Revance Performance
| RVNCDelisted Stock | USD 3.65 0.00 0.00% |
The company holds a Beta of 0.0208, which implies not very significant fluctuations relative to the market. As returns on the market increase, Revance's returns are expected to increase less than the market. However, during the bear market, the loss of holding Revance is expected to be smaller as well. Revance right now holds a risk of 4.4%. Please check Revance standard deviation, as well as the relationship between the maximum drawdown and kurtosis , to decide if Revance will be following its historical price patterns.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Revance has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Revance is not utilizing all of its potentials. The latest stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 115 M |
Revance |
Revance Relative Risk vs. Return Landscape
If you would invest 373.00 in Revance on December 1, 2024 and sell it today you would lose (8.00) from holding Revance or give up 2.14% of portfolio value over 90 days. Revance is currently generating 0.0527% in daily expected returns and assumes 4.4032% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Revance, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Revance Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Revance's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Revance, and traders can use it to determine the average amount a Revance's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.012
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | RVNC | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.4 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Revance is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Revance by adding Revance to a well-diversified portfolio.
Revance Fundamentals Growth
Revance Stock prices reflect investors' perceptions of the future prospects and financial health of Revance, and Revance fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Revance Stock performance.
| Return On Equity | -20.97 | ||||
| Return On Asset | -0.24 | ||||
| Profit Margin | (0.72) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 680.39 M | ||||
| Shares Outstanding | 104.39 M | ||||
| Price To Earning | (7.60) X | ||||
| Price To Book | 12.30 X | ||||
| Price To Sales | 1.48 X | ||||
| Revenue | 234.04 M | ||||
| EBITDA | (290.64 M) | ||||
| Cash And Equivalents | 233.82 M | ||||
| Cash Per Share | 3.20 X | ||||
| Total Debt | 478.43 M | ||||
| Debt To Equity | 2.94 % | ||||
| Book Value Per Share | (1.55) X | ||||
| Cash Flow From Operations | (216.57 M) | ||||
| Earnings Per Share | (3.34) X | ||||
| Total Asset | 478.45 M | ||||
| Retained Earnings | (2.08 B) | ||||
| Current Asset | 208.68 M | ||||
| Current Liabilities | 17.52 M | ||||
About Revance Performance
By analyzing Revance's fundamental ratios, stakeholders can gain valuable insights into Revance's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Revance has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Revance has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. Revance Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 495 people.Things to note about Revance performance evaluation
Checking the ongoing alerts about Revance for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Revance help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Revance is not yet fully synchronised with the market data | |
| Revance had very high historical volatility over the last 90 days | |
| Revance has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 234.04 M. Net Loss for the year was (323.99 M) with profit before overhead, payroll, taxes, and interest of 103.69 M. | |
| Revance currently holds about 233.82 M in cash with (216.57 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.2. | |
| Over 87.0% of the company shares are owned by institutional investors | |
| Latest headline from prnewswire.com: Revance Therapeutics, Inc. Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit |
- Analyzing Revance's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Revance's stock is overvalued or undervalued compared to its peers.
- Examining Revance's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Revance's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Revance's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Revance's stock. These opinions can provide insight into Revance's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Other Consideration for investing in Revance Stock
If you are still planning to invest in Revance check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Revance's history and understand the potential risks before investing.
| CEOs Directory Screen CEOs from public companies around the world | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |